TCT 2016: Stents, stents, stents on Day 1

Polymer-free drug-coated stent bests bare-metal stent in high bleeding risk patients

Patients at a high risk for bleeding who took a 1-month course of dual anti-platelet therapy fared better with a polymer-free drug-coated stent than with a bare metal stent after 2 years, according to results from the Leaders Free trial presented yesterday at the conference.

The study, also published in the Journal of the American College of Cardiology, compared a month of DAPT therapy and either the BioFreedom biolimus A9-coated stent made by BioSensors International or its Gazelle BMS.

The nearly 2,500-patient trial had a composite primary safety endpoint of cardiac death, myocardial infarction or stent thrombosis and a primary efficacy endpoint of clinically driven target-lesion revascularization. The primary safety endpoint at two years was 12.6% for the BioFreedom-treated cohort, compared to 15.3% for the BMS group. The results for the primary efficacy endpoint were 6.8% for the BioFreedom arm versus 12.0% for the BMS arm.

Major bleeding occurred in 8.9% of the drug-coated stent group and 9.2% of the bare metal cohort. The rate of coronary thrombotic event was 8.2% for the DCS arm and 10.6% for BMS patients. Subsequent mortality was 27.1% a year after a major bleed and 26.3% a year after a thrombotic event.

“The 2-year results from the Leaders Free trial clearly show that the use of a polymer-free biolimus A9-coated stent was both significantly safer and more effective than a bare-metal stent for patients at high risk of bleeding treated with a 1-month course of DAPT,” lead investigator Dr. Philip Urban, of Geneva’s La Tour Hospital, said in prepared remarks. “These patients suffer from a persistently high incidence of bleeding and coronary thrombotic events, both of which are associated with a high and similar mortality over a 1-year period. Therefore, identification of predictors of both the composite primary safety event and major bleeding may help design future trials of DAPT duration for this population.”

Building Better Companies at DeviceTalks Minnesota DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as: Navigating the path to market Reimbursement Winning regulatory approval Corporate culture Entering global markets Leadership Join industry leaders and medical device professionals at the most awaited medtech conference of the year, DeviceTalks Minnesota. Use code SAVE15 to save 15%! REGISTER NOW